Gavin Clark-Gartner

Gavin Clark-Gartner Analyst Performance

Managing Director, Biotechnology Equity Research at Evercore

Gavin Clark-Gartner is a stock analyst at Evercore in the healthcare sector, covering 21 publicly traded companies. Over the past year, Gavin Clark-Gartner has issued 10 stock ratings, including and buy recommendations. While full access to Gavin Clark-Gartner's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gavin Clark-Gartner's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
40 Last 2 Years
Buy Recommendations
91.89% 34 Buy Ratings
Companies Covered
21 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy2.7%1 ratings
Buy89.2%33 ratings
Hold8.1%3 ratings
Sell0.0%0 ratings

Out of 37 total stock ratings issued by Gavin Clark-Gartner at Evercore, the majority (89.2%) have been Buy recommendations, followed by 8.1% Hold and 2.7% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
90.5% of companies on NASDAQ
19 companies
NYSE
9.5% of companies on NYSE
2 companies

Gavin Clark-Gartner, an analyst at Evercore, currently covers 21 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
21 companies
100.0%

Gavin Clark-Gartner of Evercore specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
19 companies
90.5%
PHARMACEUTICALS
2 companies
9.5%

Gavin Clark-Gartner's Ratings History at Evercore

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3/4/2026Set Price Target$88.99$126.00
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2/26/2026Reiterated Rating$92.71Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
2/4/2026Lower Price Target$218.89$228.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1/20/2026Reiterated Rating$32.80$44.00Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1/20/2026Reiterated Rating$91.05$101.00Outperform
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
12/15/2025Lower Price Target$19.27$36.00Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
12/8/2025Boost Price Target$67.90$94.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
12/8/2025Boost Price Target$44.90$97.00Outperform
Evommune, Inc. stock logo
EVMN
Evommune
12/1/2025Initiated Coverage$20.71$40.00Outperform
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
11/25/2025Initiated Coverage$19.06$65.00Outperform
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
11/6/2025Reiterated Rating$18.77$38.00Outperform
argenex SE stock logo
ARGX
argenex
10/31/2025Boost Price Target$820.36$910.00Outperform
Insmed, Inc. stock logo
INSM
Insmed
10/1/2025Reiterated Rating$146.48$180.00Outperform
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
9/22/2025Lower Price Target$74.70$420.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
9/22/2025Boost Price Target$224.25$222.00Outperform
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8/8/2025Boost Price Target$59.82$89.00Outperform
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
7/11/2025Reiterated Rating$31.48$70.00Outperform
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
7/11/2025Reiterated Rating$2.32Outperform
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
7/11/2025Reiterated Rating$8.64Outperform
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
7/8/2025Lower Price Target$91.20$600.00Outperform
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/30/2025Downgrade$2.48$5.00In-Line
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
5/29/2025Initiated Coverage$11.76$46.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
5/8/2025Downgrade$36.72$50.00Inline
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
4/29/2025Initiated Coverage$1.54$5.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
4/28/2025Boost Price Target$188.39$205.00Outperform
Rallybio Corporation stock logo
RLYB
Rallybio
4/13/2025Downgrade$0.27Hold
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/18/2025Boost Price Target$150.23$260.00Outperform
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
1/28/2025Initiated Coverage$6.90$23.00Outperform
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
12/20/2024Downgrade$2.31$6.00Inline
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
12/20/2024Downgrade$1.00$5.00In-Line